Previous Close | 17.73 |
Open | 17.79 |
Bid | 17.02 x 300 |
Ask | 17.15 x 200 |
Day's Range | 17.02 - 17.79 |
52 Week Range | 7.64 - 19.68 |
Volume | |
Avg. Volume | 429,488 |
Market Cap | 733.838M |
Beta (5Y Monthly) | 0.34 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.69 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for CGEM
Strategic Developments and Financial Highlights Reflect Progress and Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma The company is exploring development of its CD19xCD3 T cell engager CLN-978 in autoimmune disorders Cash and investments of $468.3 million as of December 31, 2023 continues to provide runway into the second half of 2026 CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) -